



Jounce Therapeutics (Cambridge, MA, USA) has appointed **Deborah Law** as CSO. Law brings nearly two decades of experience in biologics drug discovery and development. She joins the company from Merck, where she most recently served as vice president of therapy area biology for immunology, oncology and immunomodulators. Prior to Merck, she was CSO for Ablynx.

“Deb’s background in immune oncology and ability to drive new candidates into development is a perfect fit for Jounce and I am thrilled to have her as part of our team,” says CEO Richard Murray.

“In addition to her subject matter expertise, her track record of executive level leadership in both small and large companies will be of substantial value as we continue to build Jounce.”

Philippe Ancian has been appointed senior director of biomarkers for contract research organization CiToxLAB (Evreux, France). He was previously senior director of the vectorology and biomarkers departments at Transgène.

Cipher Pharmaceuticals (Mississauga, Ontario, Canada) has announced the appointment of **Lynne Bulger** as vice president, medical and clinical affairs. Bulger has 27 years of experience in drug development, most recently serving as director, medical affairs at Stiefel, a GlaxoSmithKline company. Previously, she was director, medical and regulatory affairs at Barrier Therapeutics and director, medical affairs at Hoffmann-La Roche. In addition, Cipher has announced the promotions of **Peter Weiler** to the position of vice president, business development and **Linda Angaritis** to the position of vice president, global regulatory compliance and quality. Weiler and Angaritis joined Cipher in 2008 and 2013, respectively.

Eliot Forster has been appointed CEO of Immunocore Limited (Oxford, UK). He brings almost 25 years of experience in the pharma and biotech industry. He joins the company from Creabilis, where he had served as CEO since 2010. Prior roles include CEO of Solace Pharmaceuticals and head of development and operations for the EU and Asia at Pfizer.

Onconova Therapeutics (Newtown, PA, USA) has named **Steven M. Fruchtman** chief medical officer and senior vice president, R&D. Fruchtman joins Onconova from Syndax where he served as chief medical officer. He previously held senior positions at Spectrum Pharmaceuticals, Allos Therapeutics, Novartis Pharmaceuticals and Ortho Biotech.

MedDay (Paris) has appointed **Philippe Goupit** as an independent nonexecutive director. Goupit spent over 20 years at Sanofi, serving in positions including vice president, corporate licenses, head of the corporate M&A group and head of investor relations.

Batu Biologics (San Diego) has named **Alan Lewis** chairman of its board of directors. Lewis currently serves on the board of BioMarin and a number of private biotech companies. He is the past CEO of Medistem, Ambit Biosciences, Novocell, Signal Pharmaceuticals and the Juvenile Diabetes Research Foundation.

Manuel Litchman has been appointed president and CEO of Arvinas (New Haven, CT, USA). He was most recently senior vice president and global program head at Novartis Pharmaceuticals.

Atul Pande and **Roberto Solari** have been named to the board of directors of Heptares Therapeutics (Welwyn Garden City, UK). Pande is president of Verity BioConsulting and chief medical officer of Tal Medical. He was previously senior vice president and senior advisor, pharmaceutical R&D at GlaxoSmithKline. Solari is a visiting professor within the infection-in-airway-disease research group, respiratory infections section within the National Heart and Lung Institute, Imperial College London.

Raptor Pharmaceutical (Novato, CA, USA) has announced the appointment of **Krishna R. Polu** as chief medical officer and **Michael P. Smith** as CFO. Polu joins Raptor from CytomX Therapeutics, where he served as chief medical officer. Previously, he was vice

president of clinical development at Affymax. Smith most recently served as chief financial and business advisor at Catalyst Biosciences. Prior to that, he was vice president of business development at iPierian and CFO for Memory Pharmaceuticals.

Sharon Schulzki has joined Tissue Regeneration Systems (Plymouth, MI, USA) as senior vice president of business development. Most recently, she served as vice president of surgical affairs for Depuy Synthes Spine, a division of Johnson & Johnson. Previously, she was COO of medical device startup NSpine.

ContraVir Pharmaceuticals (Edison, NJ, USA) has named **John Sullivan-Bolyai** chief medical officer. Most recently, Sullivan-Bolyai was the executive director of infectious disease clinical research at Merck. He was previously vice president of clinical research at Idenix.

Claritas Genomics (Cambridge, MA, USA) has named **Patrick F. Terry** chief commercial officer. Terry is chairman of Gray Group Ventures and was a founder of Genomic Health. He was a principal with Scientia Advisors and co-founded the Personalized Medicine Coalition, European Personalized Medicine Association and the International Genetic Alliance.

Michele (Shelley) Trucksis has been appointed executive vice president and chief medical officer of microbiome therapeutics platform company Seres Health (Cambridge, MA, USA). Trucksis has over 25 years of infectious disease-focused clinical research and medical experience. She most recently served as executive director of Merck Research Laboratories with responsibility for medical, clinical and global product development functions and development strategy in antibacterials, antifungals and cytomegalovirus infections.

Oryzon Genomics (Barcelona, Spain) has named **Gregory L. Weaver** executive vice president and CFO. Weaver brings more than 30 years of industry experience, having served as CFO of several biotech companies including Fibrocell Science, Celsion, Poniard Pharmaceuticals and Sirna Therapeutics. He is a nonexecutive director of Egalet and Atossa Genetics.